AMRA Medical Introduces AMRA® BCP Scan in the Netherlands Through a Strategic Partnership with Prescan, a National Preventative Health Leader
8.1.2026 15:31:00 CET | Business Wire | Press Release
AMRA Medical, the global leader in MRI-based fat distribution and muscle composition analytics, alongside Dutch preventative healthcare leader Prescan, are pleased to announce the official launch of our cutting-edge AMRA® BCP Scan service, powered by AMRA® Profiler (CE, NB 2862), in the Netherlands. The launch, which marks BCP Scan’s third new market entry of 2025 (Sweden & Germany), expands the availability of our service within the EU into the Netherlands through an exclusive partnership with Prescan, an independent health & wellness clinic in Baarn which specializes in preventive health screenings and care.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108381985/en/
AMRA® BCP Scan available at Prescan
AMRA’s CEO, Olof Dahlqvist Leinhard, stated, “This is another important step in bringing our mission of driving scientific breakthroughs into the clinic by enabling deeper understanding of health and disease through MRI-based biomarkers to the global stage. By partnering with Prescan, we’re excited to help them empower individuals in the Netherlands to take proactive control of their health using AMRA® BCP Scan.”
The AMRA® BCP Scan service provides clinicians with fat distribution measurements, including visceral fat, subcutaneous fat and liver fat, in addition to muscle composition biomarkers that comprise a detailed body composition profile (BCP) to assist in the assessment of health risks. Implemented directly in the clinic, the service delivers rapid, precise, and standardized body composition measurements, contextualizing insights at the individual patient level with high accuracy.
At launch, Prescan will make AMRA® BCP Scan available to customers as a standalone product, and will be the only center offering BCP Scan in the Netherlands. Haif Rood Nawzad, CEO of Prescan, remarked that “This collaboration with AMRA represents an important step forward in preventive diagnostics at Prescan. By adding precise measurement of visceral fat and assisting our clinicians with assessing their metabolic risk to our offering, we further expand our advanced MRI portfolio and provide clients with clinically relevant insights that go beyond traditional imaging. It perfectly aligns with our vision to continuously innovate and improve early detection in preventive healthcare.”
Currently, AMRA® BCP Scan service is additionally available through AMRA’s service provision in the US, Canada, Sweden, Germany, the Netherlands, and the UK - with plans to roll out in more countries in 2026 and beyond.
If you or your organization are based in the currently cleared markets and would like to know more about bringing the AMRA® BCP Scan service to your clinic, or if you want to learn more about how AMRA is using MRI-based fat distribution and muscle composition measures to advance both research and clinical care, please contact us here or reach out to one of our knowledgeable scientists at info@amramedical.com.
About AMRA Medical
AMRA Medical is a global leader in health informatics, pioneering the field of fat and muscle analysis with proprietary, MRI-based technologies. Our gold-standard platform delivers highly precise and standardized biomarkers, providing an advanced understanding of metabolic and musculoskeletal health that surpasses conventional body composition metrics. These insights play a critical role in optimizing clinical trial design, improving endpoint selection, and supporting data-driven decision-making in both research and clinical practice.
Built on rigorous science and driven by continuous innovation, AMRA’s solutions are designed to meet the complex demands of modern healthcare and pharmaceutical development. Through standardized, cloud-based workflows and strategic collaboration, we enable partners to access actionable data with clarity and confidence–accelerating progress from early-stage discovery to impactful clinical outcomes.
About Prescan
Prescan is an independent preventive healthcare organization based in the Netherlands, specializing in early health detection and lifestyle advice. Founded in 2003, Prescan combines advanced MRI diagnostics with cardiology, dermatology, and blood testing. With a wide variety of examinations available, ranging from targeted scans to comprehensive full-body screenings, Prescan enables clients to gain rapid, in-depth insight into their health, with results discussed immediately by medical specialists.
You can contact Prescan with any questions you might have by filling out their contact form, or by reaching out directly to info@prescan.nl to get in touch with one of their representatives.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260108381985/en/
Contacts
MEDIA CONTACT
Marie Börjesson, VP Brand & Marketing
marie.borjesson@amramedical.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 18:09:00 CEST | Press Release
Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,
Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 12:30:00 CEST | Press Release
As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged
Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press Release
Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Stable Outlook from Fitch Ratings, assigned on 12 June 2026. Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation of the company’s
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press Release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magic Quadrant confirms the shift has moved from pilot to boardroom priority. According to Gartner, Visionaries "understands where the market
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom